Short Interest in Exagen Inc. (NASDAQ:XGN) Increases By 20.9%

Exagen Inc. (NASDAQ:XGN) saw a significant increase in short interest in September. As of September 15th, there was short interest totalling 16,800 shares, an increase of 20.9% from the August 31st total of 13,900 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average trading volume of 54,600 shares, the short-interest ratio is currently 0.3 days.

Hedge Funds Weigh In On Exagen

An institutional investor recently raised its position in Exagen stock. Renaissance Technologies LLC raised its holdings in shares of Exagen Inc. (NASDAQ:XGN) by 93.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,234 shares of the company’s stock after buying an additional 45,476 shares during the period. Renaissance Technologies LLC owned about 0.54% of Exagen worth $172,000 at the end of the most recent reporting period. 75.25% of the stock is currently owned by institutional investors.

Exagen Stock Performance

Shares of NASDAQ XGN opened at $3.14 on Friday. Exagen has a 1-year low of $1.30 and a 1-year high of $3.71. The company has a debt-to-equity ratio of 1.13, a current ratio of 4.32 and a quick ratio of 4.32. The business’s 50 day moving average is $2.78 and its two-hundred day moving average is $2.09. The stock has a market capitalization of $54.60 million, a P/E ratio of -2.88 and a beta of 1.32.

Exagen (NASDAQ:XGN) last released its quarterly earnings results on Monday, August 5th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.20. The company had revenue of $15.06 million for the quarter, compared to analyst estimates of $13.20 million. Exagen had a negative return on equity of 78.90% and a negative net margin of 30.56%. During the same quarter in the prior year, the firm posted ($0.28) EPS. As a group, research analysts expect that Exagen will post -1.02 EPS for the current year.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).